hat
Itilize nan dwòg-amelyore dwòg pa moun ki an sante nan absans la nan yon endikasyon medikal se youn nan sijè ki pi debat nan mitan neuroscientists, sikyat, ak doktè ki porte yon kantite pwoblèm, ki gen ladan etik yo ak jistis nan itilizasyon yo, enkyetid sou negatif efè, ak reyabilitasyon an nan medikaman sou preskripsyon pou itilizasyon ki pa medikal, nan mitan lòt moun. Sepandan, lavant entènasyonal nan sipleman-amelyore sipleman depase US $ 1 milya dola nan 2015 ak demann mondyal la pou sa yo konpoze toujou ap grandi rapidman.
eng
The use of cognition-enhancing drugs by healthy individuals in the absence of a medical indication is one of the most debated topics among neuroscientists, psychiatrists, and physicians which spans a number of issues, including the ethics and fairness of their use, concerns over adverse effects, and the diversion of prescription drugs for nonmedical uses, among others. Nonetheless, the international sales of cognition-enhancing supplements exceeded US$1 billion in 2015 and the global demand for these compounds is still growing rapidly.